Apidra SoloStar (Insulin Glulisine 100 U/mL) by Sanofi is a pharmaceutical-grade rapid-acting insulin analogue delivered via a prefilled SoloStar injectable pen. Insulin glulisine is a recombinant human insulin analogue with structural modifications that confer a more rapid onset and shorter duration of action relative to regular human insulin, making it a subject of clinical interest in postprandial glucose management research.
 
✔ Key Research Insights
Studied for its rapid onset of action, with documented commencement of glucose-lowering activity within 10–20 minutes of subcutaneous administration in research subjects
Investigated for its efficacy in attenuating postprandial blood glucose excursions in clinical trials involving both Type 1 and Type 2 diabetic subject populations
Researched for its flexible peri-meal administration window, with clinical protocols documenting administration within 15 minutes before or shortly after meal commencement
Examined for its pharmacokinetic profile relative to regular human insulin, with peak activity documented at approximately 1 hour and total duration of action of 3–5 hours in clinical observations
Documented for its compatibility with long-acting basal insulin formulations in basal-bolus therapy protocols referenced across international diabetes management guidelines
Manufactured by Sanofi to pharmaceutical-grade safety and consistency standards
 
📦 Product Specifications
Manufacturer: Sanofi
Product: Apidra SoloStar
Molecule: Insulin Glulisine
Concentration: 100 U/mL
Appearance: Clear, colorless injectable solution
Form: Prefilled SoloStar pen (subcutaneous injection)
Volume: Box of 5 prefilled pens
Clinical reference: dosage should be determined by a qualified healthcare professional. Subcutaneous administration is indicated within 15 minutes before or after meal commencement per documented clinical protocols.
 
⚙ How It Works
Insulin glulisine is a rapid-acting recombinant human insulin analogue in which asparagine at position B3 is replaced by lysine and lysine at position B29 is replaced by glutamic acid. These structural modifications reduce the compound's tendency to self-associate at the injection site in research subjects, facilitating faster subcutaneous absorption relative to regular human insulin. Following subcutaneous administration, insulin glulisine binds to insulin receptors on muscle and adipose tissue cells, stimulating cellular glucose uptake and suppressing hepatic glucose output. Its documented pharmacokinetic profile — onset within 10–20 minutes, peak activity at approximately 1 hour, and total duration of 3–5 hours — corresponds closely to physiological postprandial insulin secretion patterns, as noted in comparative clinical literature. In basal-bolus therapy protocols, insulin glulisine is referenced as the prandial component, administered in conjunction with a long-acting basal insulin to address both fasting and postprandial glycaemic parameters.
 
⭐ Product Overview
Manufactured by Sanofi, a globally recognized pharmaceutical company with an established presence in diabetes care and endocrinological medicine
Prefilled SoloStar pen delivery system supporting precise, consistent, and hygienic subcutaneous dosing per administration
Rapid-acting insulin analogue with a well-documented pharmacokinetic profile and established clinical efficacy in postprandial glucose management
Indicated for use in both Type 1 and Type 2 diabetes management, as referenced across international endocrinological and diabetes care guidelines
Widely recognized in clinical and regulatory literature under the insulin glulisine and Apidra designations worldwide